• Samsung EPIS Holdings unit Samsung Bioepis signed a global license, development, and commercialization deal with Teva for up to six biosimilars.
• Samsung Bioepis to develop, file, and manufacture; Teva to commercialize in the US, Europe, Canada, with an option to add territories.
• Initial confirmed candidates include SB41 referencing AstraZeneca’s Fasenra, SB44 referencing Novartis’ Ilaris.
• Deal expands an existing partnership that already commercialized EPYSQLI in the US, with OPUVIZ added for Canada.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Samsung EPIS Holdings Co. Ltd. published the original content used to generate this news brief via Business Wire (Ref. ID: 20261001835078) on October 01, 2026, and is solely responsible for the information contained therein.